Good laboratory practice (GLP) for safety tests on chemicals

AI Summary

This guidance document details the Good Laboratory Practice (GLP) compliance monitoring programme managed by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The programme is mandatory for any UK facility conducting regulatory safety studies on pharmaceuticals, chemicals, and food additives. The regulatory framework is established under the UK GLP Regulations (Statutory Instruments 1999 No. 3106 and 2004 No. 994), which are based on global OECD principles. Under these regulations, facilities are typically inspected every 12 to 30 months, with initial implementation inspections occurring within 12 weeks of a new application. Inspections assess quality systems, facilities, and study data to ensure integrity and safety. Violations are graded into three categories: Critical deficiencies, which involve systemic failures or unreliable data; Major deficiencies, representing significant departures from GLP principles that risk future compliance; and Other deficiencies, which are minor procedural deviations. Required actions for facilities include providing a verbal response during the inspection and a formal written response within 25 working days of receiving the final report. This response must detail specific corrective actions and completion dates. Serious non-compliance or evidence of fraud can lead to for-cause inspections, suspension from the compliance programme, disqualification of specific study data, or legal action led by the MHRA Enforcement Group. Facilities must also proactively notify the UK GLP Monitoring Authority of any significant organizational changes or the use of non-GLP subcontractors.